In this article
FDA Approval of Repotrectinib for ROS1-Positive NSCLC
The Food and Drug Administration authorized repotrectinib (Augtyro, Bristol-Myers Squibb Company) for locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC) on November 15, 2023.
This FDA approval is the first to encompass patients with ROS1-positive NSCLC who have previously been treated with a ROS1 tyrosine kinase inhibitor (TKI), as well as individuals who have not had TKI treatment before.
TRIDENT-1 Clinical Trial and Efficacy Results
The approval was granted following the TRIDENT-1 clinical trial (NCT03093116), a global study including many centers, with a single-arm, open-label design, and various patient cohorts with ROS1-positive locally progressed or metastatic NSCLC. The effectiveness was assessed in 71 ROS1 TKI-naïve patients who had undergone a maximum of 1 previous line of platinum-based chemotherapy and/or immunotherapy and in 56 patients who had received 1 previous ROS1 TKI without prior platinum-based chemotherapy or immunotherapy.
The primary efficacy measures were the overall response rate (ORR) and duration of response (DOR) based on RECIST v1.1 as evaluated by an impartial central review. Confirmed Objective Response Rate (ORR) was 79% (95% CI: 68, 88) in the group of patients who had not had treatment with a ROS1 TKI before and 38% (95% CI: 25, 52) in patients who had received prior treatment with a ROS1 inhibitor. The median duration of response was 34.1 months (95% CI: 25.6, not evaluable) and 14.8 months (95% CI: 7.6, not evaluable) in the two groups, respectively. Observations were made in cerebral lesions of patients with quantifiable central nervous system metastases, as well as in individuals with resistance mutations after tyrosine kinase inhibitor therapy.
Common Side Effects and Adverse Reactions
The most frequent adverse responses, occurring in over 20% of cases, were dizziness, dysgeusia, peripheral neuropathy, constipation, dyspnea, ataxia, exhaustion, cognitive problems, and muscular weakness.
Recommended Dosage and Administration
The suggested repotrectinib dosage is 160 mg taken orally once a day, with or without meals, for 14 days. Afterward, the dosage should be increased to 160 mg taken twice a day until disease progression or intolerable toxicity.
How CancerFax Helps
CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.
We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.
We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.
We support appointment coordination, document submission, translation, and direct communication with international departments.
For international patients, we help with practical coordination — travel planning, hospital admission guidance, and local support.
If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.
From inquiry through to follow-up, our coordinators provide a single point of contact for the family.
CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.
About Susan Hau
Susan Hau is a distinguished researcher in the field of cancer cell therapy, with a particular focus on T cell-based approaches and cancer vaccines. Her work spans several innovative treatment modalities, including CAR T-cell therapy, TIL (Tumor-Infiltrating Lymphocyte) therapy, and NK (Natural Killer) cell therapy. Hau's expertise lies in cancer cell biolo…
✓ Reviewed for medical accuracy by the CancerFax review panel.
Medical Disclaimer
This article is for educational purposes only and should not replace medical advice, diagnosis, or treatment from a qualified oncology specialist. Every patient's case is different. Treatment decisions should always be made after a review of complete medical records by the treating medical team.
Treatment availability, eligibility, timelines, and access can change. Any clinical trial participation depends on detailed review and approval by the trial hospital or investigator.